BackSio Gene Therapies Overview

Sio Gene Therapies Gross Profit

Latest gross profit for SIOX: $0, below the Healthcare sector average of $67B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Gross Profit

N/A

As of Dec 31, 2022

Annual Gross Profit (TTM)

N/A

Trailing 12 months ending Dec 31, 2022

Average Gross Profit (Comparison Companies)

Gross Profit History

Gross Profit Comparison

Annual Gross Profit Growth Rate (%)

Annual Gross Profit Growth (Absolute)

Sio Gene Therapies (SIOX) FAQ

As of the most recent data (December 2022), SIOX shows a gross profit of $0. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $67B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SIOX's gross profit is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Sio Gene Therapies is outperforming or lagging.

The Healthcare sector average gross profit is about $67B. Sio Gene Therapies is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how SIOX stacks up against individual peers as well.

Tracking SIOX's gross profit over time shows whether Sio Gene Therapies is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Sio Gene Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $0) with ownership activity and broader fundamentals.